×

Biotech and Pharmaceuticals Medicine

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known chemically as...

  • March 28- The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies. Wall Street analysts forecast annual sales exceeding $4 billion by 2022 for the biotech drug known...

  • TRENTON, N.J.— U.S. regulators have approved the first powerful, injected medicine to treat serious cases of the skin condition eczema. The Food and Drug Administration on Tuesday approved Dupixent for moderate or severe eczema, which causes red, fiercely itchy rashes on the face, arms and legs. Dupixent will have an initial list price of $37,000 per year, according...

  • Despite that setback for the GOP, several Republicans said Congress might revisit health care in the future, and anti-abortion leaders have stressed they will not abandon their campaign to defund Planned Parenthood. In Nevada, state lawmakers and health advocates say they will continue to promote bills that would allow women to access 12- month supplies of...

  • CHICAGO, March 27- Georgia has confirmed its first-ever case of bird flu in commercial poultry, its agriculture department said on Monday, widening an outbreak of the disease into the United States' biggest chicken meat-producing state. The discovery came after officials in Alabama, Kentucky and Tennessee confirmed cases of highly pathogenic, or lethal, and...

  • March 27- The U.S. Food and Drug Administration on Monday approved Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer. The U.S. biopharmaceutical company's shares were up 7.78 percent at $168.9 in extended trading. Tesaro expects to launch niraparib in the United States in late April.

  • March 27- The U.S. Food and Drug Administration on Monday approved Tesaro Inc's drug, niraparib, for the treatment of recurrent ovarian cancer.

  • By Divya Grover and Natalie Grover. March 27- Foamix Pharmaceuticals Ltd said on Monday its experimental acne treatment failed to meet one of two main goals in a late-stage study, pushing its shares down about 42 percent. However, the drug, FMX101, succeeded in a separate late-stage study, the Israel- based drug developer said.

  • LONDON, March 27- International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. If the latest patent challenge is successful, it could make cheaper generic versions of sofosbuvir available in...

  • March 27- Foamix Pharmaceuticals Ltd said its experimental acne drug failed to meet one of two main goals in a late-stage study, sending its shares down about 30 percent in premarket trading. However, the drug, FMX101, induced a statistically significant benefit in a separate late-stage study, the Israel- based drug developer said. Acne is the most common skin...

  • *Mutation very common China, opening big sales opportunity. LONDON, March 27- AstraZeneca has won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine. Tagrisso is designed to help cancer patients with certain genetic mutations that are very common in China and the regulatory green light boosts the British...

  • LONDON, March 27- AstraZeneca said on Monday it had won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.

  • March 24- Xenon Pharmaceuticals Inc's shares tumbled 45 percent in premarket trading on Friday after the drug developer said it would discontinue developing its acne drug as it failed to meet the main goal in a mid-stage study. Acne is the most common skin condition in the United States, affecting up to 50 million Americans annually, according to the American...

  • March 24- Xenon Pharmaceuticals Inc said on Friday it would abandon its acne drug, after it failed to meet the main goal in a mid-stage study. The drug, XEN801, which was tested against a placebo, did not induce a statistically significant effect in treating moderate to severe facial acne. Acne is the most common skin condition in the United States, affecting up to 50...

  • A first responder for Livingston County Michigan, draws the blood of Amaria Roberson, age 5 of Flint, to screen her blood for lead on January 26, 2016 at Eisenhower Elementary School in Flint, Michigan. Free lead screenings are performed for Flint children 6-years-old and younger, one of several events sponsored by Molina Healthcare following the city's water contamination and federal state of emergency.

    As Republicans tried to muster support for their health-care bill on Thursday, one insurance executive told CNBC the measure is a bad idea.

  • The Food and Drug Administration said it approved Bavencio, known chemically as avelumab, to treat metastatic Merkel cell carcinoma in patients 12 years and older. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in a statement. About 1,600 people in the United States are diagnosed with MCC every year, according to the National Cancer...

  • March 22- Ultragenyx Pharmaceutical Inc said its drug to treat patients with seizures did not meet the main goal in a mid-stage study, sending its shares down 6.2 percent in after-market trading on Wednesday. The company said the study did not show statistical significance in reducing the frequency of seizures among patients treated with the drug compared to...

  • BOSTON— The former head of a Massachusetts pharmacy was acquitted Wednesday of murder allegations but convicted of racketeering and other crimes in a meningitis outbreak that was traced to fungus-contaminated drugs and killed 64 people across the country. Indiana, Michigan and Tennessee were hit hardest. Joan Peay, 76, of Nashville, Tennessee, suffered two...

  • *Trial failure trims Novartis blockbuster hopefuls to 12. *Some traders say failed drug had $2 bln/ year potential. ZURICH, March 22- Novartis's heart failure drug serelaxin flopped in a late-stage trial by not cutting cardiovascular death or slowing disease progression, marking the likely demise of a drug hopeful the Swiss firm had promoted as a potential...

  • ZURICH, March 22- Novartis' efforts to expand its heart treatment franchise beyond its flagship Entresto business suffered a blow when it announced on Wednesday its acute heart failure drug serelaxin had failed in a late-stage trial. Serelaxin, once seen a potential blockbuster, suffered a string of setbacks in 2014 when European Union health regulators and...